company background image
3008

Imeik Technology DevelopmentLtd SZSE:300896 Stock Report

Last Price

CN¥547.24

Market Cap

CN¥118.4b

7D

2.2%

1Y

-20.7%

Updated

22 Jun, 2022

Data

Company Financials +
300896 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance6/6
Financial Health6/6
Dividends2/6

300896 Stock Overview

Imeik Technology Development Co.,Ltd focuses on the research and development, production, and sale of biomedical materials.

Rewards

Earnings are forecast to grow 37.77% per year

Earnings grew by 88.1% over the past year

Risk Analysis

No risks detected for 300896 from our risk checks.

Imeik Technology DevelopmentLtd Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Imeik Technology DevelopmentLtd
Historical stock prices
Current Share PriceCN¥547.24
52 Week HighCN¥844.44
52 Week LowCN¥391.09
Beta0
1 Month Change12.37%
3 Month Change21.66%
1 Year Change-20.71%
3 Year Changen/a
5 Year Changen/a
Change since IPO189.63%

Recent News & Updates

Shareholder Returns

300896CN BiotechsCN Market
7D2.2%3.6%-0.1%
1Y-20.7%-33.5%-11.9%

Return vs Industry: 300896 exceeded the CN Biotechs industry which returned -32.7% over the past year.

Return vs Market: 300896 underperformed the CN Market which returned -10.6% over the past year.

Price Volatility

Is 300896's price volatile compared to industry and market?
300896 volatility
300896 Average Weekly Movement6.8%
Biotechs Industry Average Movement7.2%
Market Average Movement7.1%
10% most volatile stocks in CN Market10.1%
10% least volatile stocks in CN Market5.0%

Stable Share Price: 300896 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 300896's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004507Yifeng Shihttps://www.imeik.net

Imeik Technology Development Co.,Ltd focuses on the research and development, production, and sale of biomedical materials. The company offers medical beauty field products, including Moisten Angel, IFRESH, Yimei, Hearty, Bonita Bonita, and Tightly. It also offers skin care products, including moisturizing lotions, anti-wrinkle firming kinetic energy liquids, essence creams, hydrating firming masks, chitosan B5 repair sprays, and purifying and brightening kinetic liquids.

Imeik Technology DevelopmentLtd Fundamentals Summary

How do Imeik Technology DevelopmentLtd's earnings and revenue compare to its market cap?
300896 fundamental statistics
Market CapCN¥118.40b
Earnings (TTM)CN¥1.07b
Revenue (TTM)CN¥1.62b

111.0x

P/E Ratio

73.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
300896 income statement (TTM)
RevenueCN¥1.62b
Cost of RevenueCN¥95.73m
Gross ProfitCN¥1.52b
Other ExpensesCN¥456.37m
EarningsCN¥1.07b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)4.93
Gross Margin94.09%
Net Profit Margin65.90%
Debt/Equity Ratio0.2%

How did 300896 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

43%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 300896 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300896?

Other financial metrics that can be useful for relative valuation.

300896 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue70.8x
Enterprise Value/EBITDA98.8x
PEG Ratio2.9x

Price to Earnings Ratio vs Peers

How does 300896's PE Ratio compare to its peers?

300896 PE Ratio vs Peers
The above table shows the PE ratio for 300896 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average78.6x

Price-To-Earnings vs Peers: 300896 is expensive based on its Price-To-Earnings Ratio (111x) compared to the peer average (78.6x).


Price to Earnings Ratio vs Industry

How does 300896's PE Ratio compare vs other companies in the Chinese Biotechs Industry?

Price-To-Earnings vs Industry: 300896 is expensive based on its Price-To-Earnings Ratio (111x) compared to the CN Biotechs industry average (38.7x)


Price to Earnings Ratio vs Fair Ratio

What is 300896's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300896 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio111x
Fair PE Ratio47.9x

Price-To-Earnings vs Fair Ratio: 300896 is expensive based on its Price-To-Earnings Ratio (111x) compared to the estimated Fair Price-To-Earnings Ratio (47.9x).


Share Price vs Fair Value

What is the Fair Price of 300896 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300896 (CN¥547.24) is trading above our estimate of fair value (CN¥319.02)

Significantly Below Fair Value: 300896 is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: 300896 is poor value based on its PEG Ratio (2.9x)


Discover undervalued companies

Future Growth

How is Imeik Technology DevelopmentLtd forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

6/6

Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


37.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300896's forecast earnings growth (37.8% per year) is above the savings rate (3.3%).

Earnings vs Market: 300896's earnings (37.8% per year) are forecast to grow faster than the CN market (23.9% per year).

High Growth Earnings: 300896's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300896's revenue (39.6% per year) is forecast to grow faster than the CN market (17.4% per year).

High Growth Revenue: 300896's revenue (39.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 300896's Return on Equity is forecast to be high in 3 years time (28.6%)


Discover growth companies

Past Performance

How has Imeik Technology DevelopmentLtd performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


42.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 300896 has high quality earnings.

Growing Profit Margin: 300896's current net profit margins (65.9%) are higher than last year (63.8%).


Past Earnings Growth Analysis

Earnings Trend: 300896's earnings have grown significantly by 42.3% per year over the past 5 years.

Accelerating Growth: 300896's earnings growth over the past year (88.1%) exceeds its 5-year average (42.3% per year).

Earnings vs Industry: 300896 earnings growth over the past year (88.1%) exceeded the Biotechs industry 11.3%.


Return on Equity

High ROE: 300896's Return on Equity (20.2%) is considered high.


Discover strong past performing companies

Financial Health

How is Imeik Technology DevelopmentLtd's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 300896's short term assets (CN¥4.0B) exceed its short term liabilities (CN¥149.4M).

Long Term Liabilities: 300896's short term assets (CN¥4.0B) exceed its long term liabilities (CN¥80.1M).


Debt to Equity History and Analysis

Debt Level: 300896 has more cash than its total debt.

Reducing Debt: 300896's debt to equity ratio has reduced from 1% to 0.2% over the past 5 years.

Debt Coverage: 300896's debt is well covered by operating cash flow (9083%).

Interest Coverage: 300896 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Imeik Technology DevelopmentLtd current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.38%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 300896's dividend (0.38%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.49%).

High Dividend: 300896's dividend (0.38%) is low compared to the top 25% of dividend payers in the CN market (1.97%).


Stability and Growth of Payments

Stable Dividend: Too early to tell whether 300896's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if 300896's dividend payments are increasing as they only just started paying a dividend.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (42.6%), 300896's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (45.5%), 300896's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CN¥4m

CEO Compensation


CEO

Yifeng Shi (48 yo)

no data

Tenure

CN¥3,704,600

Compensation

Mr. Shi Yifeng serves as Director and General Manager at Imeik Technology Development Co.,Ltd.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Imeik Technology Development Co.,Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Imeik Technology Development Co.,Ltd.
  • Ticker: 300896
  • Exchange: SZSE
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CN¥118.401b
  • Shares outstanding: 216.36m
  • Website: https://www.imeik.net

Number of Employees


Location

  • Imeik Technology Development Co.,Ltd.
  • Shimao Building
  • Floor 21st, Block C
  • Beijing
  • 100022
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/22 00:00
End of Day Share Price2022/06/22 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.